SPUVE Inhibitors
Chemical inhibitors of SPUVE can exert their inhibitory effects through various mechanisms by modulating the cellular protease environment. Pepstatin A, for example, aligns itself with the aspartic protease class to which SPUVE belongs, directly binding to its active site and impeding substrate cleavage. This binding is highly specific and prevents SPUVE from performing its proteolytic function. Similarly, E64, though a cysteine protease inhibitor, can indirectly inhibit SPUVE by causing an accumulation of proteins within the cell that may interact with SPUVE, potentially leading to steric hindrance. This could result in the functional inhibition of SPUVE's enzymatic activity, as the protease is unable to access its substrates.
Additionally, inhibitors like Leupeptin, Antipain, Chymostatin, and Aprotinin primarily target cysteine and serine proteases. Their inhibition can lead to increased levels of intracellular proteins that, while not direct inhibitors of aspartic proteases, could nonetheless compete with SPUVE for substrate binding or alter the protease-antiprotease balance, thereby indirectly limiting SPUVE's activity. AEBSF and 3,4-Dichloroisocoumarin function similarly by disrupting the proteolytic pathway, causing an imbalance that leads to the accumulation of proteins or peptides that may competitively inhibit SPUVE's activity. Compounds like Gabexate mesylate and Camostat mesylate further contribute to this effect, as the buildup of substrates within the protease network can interfere with SPUVE's function, either by directly blocking its active site or through allosteric effects that reduce its enzymatic efficiency. Lastly, metalloprotease inhibitors such as Phosphoramidon and Marimastat, despite not being direct inhibitors of aspartic proteases, can influence SPUVE indirectly. They can increase the concentration of peptides and proteins that could obstruct SPUVE's substrate-binding sites or induce conformational changes in SPUVE, leading to reduced proteolytic function.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
E-64 | 66701-25-5 | sc-201276 sc-201276A sc-201276B | 5 mg 25 mg 250 mg | $281.00 $947.00 $1574.00 | 14 | |
E64 is a potent inhibitor of cysteine proteases. Although SPUVE is an aspartic protease, the inhibition of cysteine proteases can lead to the accumulation of proteins that may physically interact with SPUVE or its substrates, potentially leading to steric hindrance and the functional inhibition of SPUVE's enzymatic activity. | ||||||
Leupeptin hemisulfate | 103476-89-7 | sc-295358 sc-295358A sc-295358D sc-295358E sc-295358B sc-295358C | 5 mg 25 mg 50 mg 100 mg 500 mg 10 mg | $73.00 $148.00 $316.00 $499.00 $1427.00 $101.00 | 19 | |
Leupeptin is an inhibitor that targets serine and cysteine proteases. It can inhibit SPUVE indirectly by stabilizing proteins that might compete with SPUVE for substrate binding or by altering the protease-antiprotease equilibrium in the cell, thereby hindering SPUVE's protease activity. | ||||||
Chymostatin | 9076-44-2 | sc-202541 sc-202541A sc-202541B sc-202541C sc-202541D | 5 mg 10 mg 25 mg 50 mg 100 mg | $156.00 $260.00 $640.00 $1186.00 $2270.00 | 3 | |
Chymostatin is a chymotrypsin inhibitor that, by inhibiting a broad range of proteases including serine proteases, may cause an indirect inhibition of SPUVE. The accumulation of protease substrates or interacting proteins in the cell can impair SPUVE's function through non-specific interactions or competitive inhibition. | ||||||
Aprotinin | 9087-70-1 | sc-3595 sc-3595A sc-3595B | 10 mg 100 mg 1 g | $112.00 $408.00 $3000.00 | 51 | |
Aprotinin, a protease inhibitor, primarily targets serine proteases. By inhibiting these proteases, it can result in increased levels of proteins that may bind to and inhibit SPUVE through allosteric effects or substrate competition. | ||||||
AEBSF hydrochloride | 30827-99-7 | sc-202041 sc-202041A sc-202041B sc-202041C sc-202041D sc-202041E | 50 mg 100 mg 5 g 10 g 25 g 100 g | $65.00 $122.00 $428.00 $851.00 $1873.00 $4994.00 | 33 | |
AEBSF is a serine protease inhibitor that could indirectly inhibit SPUVE by causing an imbalance in the proteolytic pathway, leading to the accumulation of molecules that could competitively inhibit SPUVE's proteolytic activity. | ||||||
Gabexate mesylate | 56974-61-9 | sc-215066 | 5 mg | $100.00 | ||
As an inhibitor of serine proteases, Gabexate mesylate's primary mechanism is to prevent protease-mediated cleavage. The inhibition of these proteases can lead to an indirect inhibition of SPUVE by altering the cellular balance of proteases and their substrates, potentially leading to a functional inhibition of SPUVE. | ||||||
Camostat mesylate | 59721-29-8 | sc-203867 sc-203867A sc-203867B sc-203867C sc-203867D sc-203867E | 10 mg 50 mg 500 mg 1 g 10 g 100 g | $43.00 $183.00 $312.00 $624.00 $2081.00 $4474.00 | 5 | |
Camostat mesylate is known to inhibit serine proteases. Its use can result in the buildup of protease substrates or regulatory proteins within the cell, which could interfere with SPUVE's activity via competitive inhibition or allosteric modulation of its function. | ||||||
Phosphoramidon | 119942-99-3 | sc-201283 sc-201283A | 5 mg 25 mg | $199.00 $632.00 | 8 | |
Phosphoramidon is a metalloprotease inhibitor that can lead to an increase in peptide substrates or binding proteins in the cell, which may inhibit SPUVE's function by binding to its substrate-binding site or by inducing conformational changes that reduce its enzymatic activity. | ||||||
Marimastat | 154039-60-8 | sc-202223 sc-202223A sc-202223B sc-202223C sc-202223E | 5 mg 10 mg 25 mg 50 mg 400 mg | $168.00 $218.00 $404.00 $629.00 $4900.00 | 19 | |
Marimastat is a broad-spectrum metalloprotease inhibitor. Although its primary targets are not aspartic proteases, its effect on the protease network within the cell may lead to an accumulation of proteins that could hinder SPUVE's enzymatic activity through non-specific binding or competitive inhibition. | ||||||